News about Global Pharma

Biocon's S&P Global ESG Score Improves to 69 for 2024, Up by 6 Points from 2023

Biocon Ltd., a global biopharmaceutical company, achieved a 6-point rise in its S&P Global ESG Score to 69 in 2024, ranking in the 98th percentile among biotechnology peers, with standout scores in Environmental (76), Social (74), and Governance (62) dimensions.

Global Pharma | 27/01/2025 | By Manvi |  279

Zydus's Chairman Pankaj R Patel Conferred with Padma Bhushan

With a Masters in Pharmaceutics and Pharmaceutical Technology from the L.M. College of Pharmacy and an alumni of the Indian Institute of Management (IIM), Ahmedabad, he was always driven by a passion to become a pharma entrepreneur.

Global Pharma | 27/01/2025 | By Aishwarya |  681

AstraZeneca To Invest CAD 820 Mn in Canada to Boost Clinical Delivery Sector

New investment in Canada will contribute to AstraZeneca’s global ambition to achieve USD80 billion in Total Revenue and to bring 20 new medicines to patients around the world by 2030 of which eight new medicines have been delivered to date.

Global Pharma | 27/01/2025 | By Aishwarya |  481

CStone Join Hands with SteinCares to Commercialize Sugemalimab in Latin America

As part of this collaboration, SteinCares will be responsible for the regulatory affairs and commercialization activities of sugemalimab in these regions.

Global Pharma | 27/01/2025 | By Aishwarya |  445

AbbVie Finalises Acquisition of Nimble Therapeutics

AbbVie has completed its acquisition of Nimble Therapeutics, adding Nimble's novel oral peptide IL23R inhibitor for psoriasis and proprietary peptide discovery platform to its immunology pipeline.

Global Pharma | 24/01/2025 | By Manvi |  449

Veeva and Zifo to Accelerate Quality Control Modernization

By bringing together Veeva LIMS with Zifo’s data integration and management platform, qcKen, companies can import data directly from any source document or other LIMS into Veeva LIMS.

Global Pharma | 24/01/2025 | By Aishwarya |  954

Medix Biochemica Announces Acquisition of CANDOR Bioscience

The acquisition both strengthens Medix Biochemica’s range of high-quality raw materials to the worldwide IVD industry and enhances its capabilities to support test manufacturers in immunoassay development.

Global Pharma | 24/01/2025 | By Aishwarya |  441

Piramal Critical Care Launches Chlorpromazine Hydrochloride for Injection, USP in US

Piramal Critical Care (PCC), a division of Piramal Pharma Ltd., has launched Chlorpromazine Hydrochloride for Injection, USP to be offered in 25mg/1mL and 50mg/2mL vials in the US, expanding its generic injectables portfolio.

Global Pharma | 23/01/2025 | By Manvi |  307

Zydus Announces USFDA Orphan Drug Designation to Usnoflast for Treatment of ALS

Zydus has received USFDA Orphan Drug Designation for Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic lateral sclerosis (ALS).

Global Pharma | 23/01/2025 | By Manvi |  350

Conduit and Agility to Develop Enhanced Formulations for its Autoimmune Pipeline

Conduit has developed a series of novel, advantageous solid forms of all its autoimmune pipeline assets, each protected by newly established composition-of-matter intellectual property (IP).

Global Pharma | 23/01/2025 | By Aishwarya |  635